| # | Title | Journal | Year | Citations |
|---|
| 1 | EuroQol - a new facility for the measurement of health-related quality of life | Health Policy | 1990 | 12,704 |
| 2 | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) | Quality of Life Research | 2011 | 5,877 |
| 3 | Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses | JAMA - Journal of the American Medical Association | 2016 | 2,149 |
| 4 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force | Value in Health | 2013 | 1,657 |
| 5 | Guidelines for authors and peer reviewers of economic submissions to the BMJ | BMJ: British Medical Journal | 1996 | 1,472 |
| 6 | Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets | Value in Health | 2012 | 1,381 |
| 7 | beta Blockade after myocardial infarction: systematic review and meta regression analysis | BMJ: British Medical Journal | 1999 | 1,211 |
| 8 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement | BMJ, The | 2013 | 1,082 |
| 9 | Variations in population health status: results from a United Kingdom national questionnaire survey | BMJ: British Medical Journal | 1998 | 905 |
| 10 | Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis | BMJ: British Medical Journal | 2000 | 905 |
| 11 | Representing uncertainty: the role of cost-effectiveness acceptability curves | Health Economics (United Kingdom) | 2001 | 885 |
| 12 | Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility | Health Economics (United Kingdom) | 2005 | 750 |
| 13 | An Introduction to Markov Modelling for Economic Evaluation | Pharmacoeconomics | 1998 | 713 |
| 14 | Overcoming barriers to health service access: influencing the demand side | Health Policy and Planning | 2004 | 644 |
| 15 | Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire | Quality of Life Research | 1993 | 617 |
| 16 | Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research | Value in Health | 2016 | 589 |
| 17 | Fitting Mixed Logit Models by Using Maximum Simulated Likelihood | The Stata Journal | 2007 | 580 |
| 18 | The time trade-off method: Results from a general population study | Health Economics (United Kingdom) | 1996 | 579 |
| 19 | Model Parameter Estimation and Uncertainty Analysis | Medical Decision Making | 2012 | 564 |
| 20 | Intergenerational Equity: An Exploration of the ‘Fair Innings’ Argument | | 1997 | 547 |
| 21 | Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold | Health Technology Assessment | 2015 | 536 |
| 22 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement | Value in Health | 2013 | 513 |
| 23 | Knowledge, Attitude and Practice Toward COVID-19 Among the Public in the Kingdom of Saudi Arabia: A Cross-Sectional Study | Frontiers in Public Health | 2020 | 512 |
| 24 | Review of guidelines for good practice in decision-analytic modelling in health technology assessment | Health Technology Assessment | 2004 | 511 |
| 25 | Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life | | 1997 | 482 |
| 26 | Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 | Value in Health | 2012 | 478 |
| 27 | Equity of access to health care services: | Social Science and Medicine | 2001 | 462 |
| 28 | A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials | Pharmacoeconomics | 2014 | 417 |
| 29 | A comparison of approaches to estimating confidence intervals for willingness to pay measures | Health Economics (United Kingdom) | 2007 | 410 |
| 30 | Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report | Value in Health | 2009 | 395 |
| 31 | Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment | Pharmacoeconomics | 2006 | 390 |
| 32 | Contamination in trials: is cluster randomisation the answer? | BMJ: British Medical Journal | 2001 | 387 |
| 33 | A rational framework for decision making by the National Institute For Clinical Excellence (NICE) | Lancet, The | 2002 | 378 |
| 34 | South Korean Time Trade-Off Values for EQ-5D Health States: Modeling with Observed Values for 101 Health States | Value in Health | 2009 | 375 |
| 35 | The dynamics of health in the British Household Panel Survey | Journal of Applied Econometrics | 2004 | 369 |
| 36 | Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra | Health Economics (United Kingdom) | 2005 | 368 |
| 37 | Generalisability in economic evaluation studies in healthcare: a review and case studies | Health Technology Assessment | 2004 | 361 |
| 38 | Key principles for the improved conduct of health technology assessments for resource allocation decisions | International Journal of Technology Assessment in Health Care | 2008 | 356 |
| 39 | Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis | Pharmacoeconomics | 2006 | 352 |
| 40 | What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews | BMJ: British Medical Journal | 2004 | 349 |
| 41 | QALY maximisation and people's preferences: a methodological review of the literature | Health Economics (United Kingdom) | 2005 | 324 |
| 42 | Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences | BMJ: British Medical Journal | 1999 | 319 |
| 43 | The measurement of patient satisfaction | Journal of Public Health Medicine | 1992 | 314 |
| 44 | Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: Acute-phase outcomes | British Journal of Psychiatry | 2002 | 311 |
| 45 | Whither trial-based economic evaluation for health care decision making? | Health Economics (United Kingdom) | 2006 | 302 |
| 46 | Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia | BMJ: British Medical Journal | 2000 | 296 |
| 47 | Introducing economic and quality of life measurements into clinical studies | Annals of Medicine | 2001 | 296 |
| 48 | The effectiveness and cost effectiveness of a national lay-led self care support programme for patients with long-term conditions: a pragmatic randomised controlled trial | Journal of Epidemiology and Community Health | 2007 | 287 |
| 49 | Should we pay the patient? Review of financial incentives to enhance patient compliance | BMJ: British Medical Journal | 1997 | 282 |
| 50 | Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer | Health Technology Assessment | 2011 | 266 |
